<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00081731</url>
  </required_header>
  <id_info>
    <org_study_id>161</org_study_id>
    <secondary_id>U01HL071556</secondary_id>
    <nct_id>NCT00081731</nct_id>
  </id_info>
  <brief_title>Benefits of Medical Therapy Plus Stenting for Renal Atherosclerotic Lesions</brief_title>
  <acronym>CORAL</acronym>
  <official_title>Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baim Institute for Clinical Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Baim Institute for Clinical Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare medical therapy plus stenting of hemodynamically significant renal
      artery stenoses versus medical therapy alone in patients with systolic hypertension and renal
      artery stenosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND:

      Atherosclerotic renal artery stenosis is a common problem for which there is no clear
      consensus on diagnosis or therapy. There likely exists a progression in which renal ischemia
      leads to neuroendocrine activation, hypertension, and renal insufficiency resulting in
      acceleration of atherosclerosis, further renal dysfunction, and development of left
      ventricular hypertrophy. These events in turn lead to adverse clinical events.

      Renal artery stenosis is one of the two major known causes of hypertension and occurs in 1-5%
      of hypertensive patients. In patients with accelerated hypertension, the prevalence of renal
      artery stenosis is much higher, ranging from 10-40%. Renal artery stenosis, when occurring
      bilaterally, or in a solitary kidney, is a significant cause for end-stage renal disease,
      accounting for several percent of patients with end-stage renal disease. Clinically,
      atherosclerotic renal artery stenosis is a major problem primarily in older patients, and is
      often seen in long-standing hypertensives whose blood pressure becomes very difficult to
      control. Of major significance is the progressive nature of atherosclerotic renal artery
      stenosis, progressing at the rate of about 10% per year (45-60% progression rate in 4-7 year
      follow-ups). Over this time period, 10-15% of patients develop total renal artery occlusion.
      If the renal artery stenosis is greater than 75% when detected, 40% of patients develop total
      occlusion. Due to the progressive nature of atherosclerotic lesions, the decline in renal
      function in some individuals, and difficult-to-control hypertension, the medical community
      has sought to detect those patients in whom intervention would be beneficial. This has been
      extremely difficult to achieve and tests to date have not been uniformly predictive,
      including peripheral vein plasma renin activity, renal vein renin activity,
      captopril-stimulated nuclear medicine renal scans, etc.

      Since approximately 50% of patients with unilateral renal artery stenosis of significant
      degree (definitions vary) benefit from surgical intervention, enthusiasm has continued with
      the advent of renal artery angioplasty. The entire field is moving very quickly. However,
      there are neither current data nor prospective studies indicating the benefit of renal artery
      angioplasty plus stents. Studies over the last decade have shown that balloon angioplasty
      alone is associated with a high rate of recurrence in patients with atherosclerotic renal
      artery stenosis. In the present climate, there is great enthusiasm to perform angioplasty
      plus stent placement in atherosclerotic renal artery stenosis, without supporting data for
      efficacy compared to medical management alone. Angioplasty and stent placement in the renal
      arteries had been the domain of interventional radiologists, but recently, interventional
      cardiologists are also performing these procedures. The questions as to who will benefit from
      intervention and which intervention to use have not been answered. Renal artery angioplasty
      and stent placement subjects the patient to procedural risks, as well as increased cost, when
      compared to aggressive antihypertensive medication and risk factor medication and therapy.

      DESIGN NARRATIVE:

      This randomized, multicenter clinical trial will contrast the effect of optimal medical
      therapy alone to stenting with optimal medical therapy, on a composite of cardiovascular and
      renal endpoints: cardiovascular or renal death, myocardial infarction, hospitalization for
      congestive heart failure, stroke, doubling of serum creatinine level, and need for renal
      replacement therapy. These endpoints will be evaluated by a clinical events committee masked
      to treatment assignment. The secondary endpoints will 1) evaluate the mechanisms linked to
      clinical events; 2) describe differential effectiveness in critical end-organs; 3) determine
      the value of stenting from the patient and the health policy perspectives, measured as
      quality of life and cost-effectiveness; and 4) evaluate for clinically relevant differences
      in treatment effectiveness within the primary endpoint.

      Patients will undergo a baseline evaluation to determine eligibility. Approximately 1,080
      patients will be randomized to optimal medical therapy alone or to stenting with optimal
      medical therapy at an estimated 100 clinical sites. Initially, patients will be followed at
      2-week intervals, until blood pressure is at target or up to 2 months. Follow-up visits will
      be mandated at 2 weeks, every 3 months for the first year and annually thereafter.
      Coordinator visits will also occur semi-annually.

      The CORAL Study Chair is Lance Dworkin, MD, Brown University, Providence, RI. The CORAL Study
      Co-Chair is William Henrich, MD, University of Texas, San Antonio, TX. The Principal
      Investigators of the CORAL Clinical Coordinating Center are Christopher Cooper, MD,
      University of Toledo Health Science Campus, Toledo OH, and Timothy Murphy, MD, Brown
      University, Providence, RI.

      The Principal Investigator of the Angiographic Core Laboratory is Alan Matsumoto, MD,
      University of Virginia, Charlottesville, VA. The Principal Investigator of the GFR and
      Biochemistry Core Laboratory is Michael Steffes, MD, University of Minnesota, Minneapolis,
      MN. The Principal Investigator of the Economics and Quality of Life Core Laboratory is David
      Cohen, MD, Mid-America Heart Institute, St. Luke's Hospital, Kansas City, MO. The Principal
      Investigator of the Data Coordinating Center is Donald Cutlip, MD, Beth Israel Deaconess
      Medical Center, Boston, MA. For additional information about the CORAL trial, please refer to
      the CORAL website (link given below).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2004</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite Endpoint: Death From Cardiovascular or Renal Causes, Stroke, Myocardial Infarction, Hospitalization for CHF, Progressive Renal Insufficiency, or Permanent Renal Replacement Therapy</measure>
    <time_frame>Measured at every 3 months for the first year and annually thereafter</time_frame>
    <description>Only the first event per participant is included in the composite</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiovascular or Renal Death</measure>
    <time_frame>Measured at every 3 months for the first year and annually thereafter</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Myocardial Infarction</measure>
    <time_frame>Measured at every 3 months for the first year and annually thereafter</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Hospitalization for Congestive Heart Failure</measure>
    <time_frame>Measured at every 3 months for the first year and annually thereafter</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Stroke</measure>
    <time_frame>Measured at every 3 months for the first year and annually thereafter</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>30% Reduction of eGFR From Baseline, Persisting for Greater Than or Equal to 60 Days</measure>
    <time_frame>Measured at every 3 months for the first year and annually thereafter</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Need for Renal Replacement Therapy</measure>
    <time_frame>Measured at every 3 months for the first year and annually thereafter</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">947</enrollment>
  <condition>Atherosclerosis</condition>
  <condition>Cardiovascular Diseases</condition>
  <condition>Hypertension, Renovascular</condition>
  <condition>Renal Artery Obstruction</condition>
  <arm_group>
    <arm_group_label>Optimal Medical Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Optimal anti-hypertensive therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stenting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stent procedure plus optimal anti-hypertensive therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atacand/HCT, Caduet</intervention_name>
    <description>Atacand/HCT and caduet or optimal medical therapy for hypertension</description>
    <arm_group_label>Optimal Medical Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>GENESISTM Embolic Protection Stent and Angioguard Device (Angioplasty plus stenting)</intervention_name>
    <description>Angioplasty plus stenting of the renal artery GENESISTM Embolic Protection Stent and Angioguard Device</description>
    <arm_group_label>Stenting</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:

          1. Either

               1. Documented history of hypertension on two or more anti-hypertensive medications
                  OR

               2. Renal dysfunction, defined as Stage 3 or greater chronic kidney disease (CKD)
                  based on the new National Kidney Foundation (NKF) classifications (estimated
                  glomerular filtration rate [GFR] less than 60 mL per minute per 1.73 m^2,
                  calculated by the modified Modification of Diet in Renal Disease [MDRD] formula)

          2. One or more severe renal artery stenoses by any of the following pathways:

             a. Angiographic: greater than or equal to 60% and less than 100% by renal angiogram OR
             b. Duplex: systolic velocity of greater than 300 cm/sec OR c. Core Lab approved
             Magnetic Resonance Angiogram (MRA) (refer to the protocol for specific criteria)
             demonstrating stenosis greater than 80% OR stenosis greater than 70% with spin
             dephasing on 3D phase contrast MRA OR stenosis greater than 70% and two of the
             following: i. Ischemic kidney is greater than 1 cm. smaller than contralateral kidney
             ii. Ischemic kidney enhances less on arterial phase iii. Ischemic kidney has delayed
             Gd excretion iv. Ischemic kidney hyper-concentrates the urine v. 2-D phase contrast
             flow waveform shows delayed systolic peak vi. Post-stenotic dilatation d. Clinical
             index of suspicion combined with a Core Lab approved Computed Tomography Angiography
             (CTA) demonstrating Stenosis is greater than 80% by visual assessment on high quality
             CTA Stenosis is greater than 70% on CTA by visual assessment and there are two of the
             following i. The length of the ischemic kidney is greater than 1 cm. smaller than
             contralateral kidney ii. Reduced cortical thickness of ischemic kidney iii. Less
             cortical enhancement of ischemic kidney on arterial phase iv. Post-stenotic dilatation

        EXCLUSION CRITERIA:

          1. Unable to provide informed consent

          2. Unable or willing to comply with study protocol or procedures

          3. Must be greater than 18 years of age

          4. Fibromuscular dysplasia or other non-atherosclerotic renal artery stenosis known to be
             present prior to randomization

          5. Pregnancy or unknown pregnancy status in female of childbearing potential

          6. Participation in any drug or device trial during the study period, unless approved by
             the Steering Committee

          7. Prior enrollment in the CORAL study

          8. History of stroke within 6 months, if associated with a residual neurologic deficit*

          9. Any major surgery, major trauma, revascularization procedure, unstable angina, or
             myocardial infarction 30 days prior to study entry*

         10. Any planned major surgery or revascularization procedure, outside of the randomly
             allocated renal stenting indicated by the protocol, after randomization*

         11. Hospitalization for heart failure within 30 days*

         12. Comorbid condition causing life expectancy of less than or equal to 3 years*

         13. Allergic reaction to intravascular contrast, not amenable to pre-treatment

         14. Allergy to stainless steel

         15. Allergy to all of the following: aspirin, clopidogrel, ticlopidine

         16. Known untreated aneurysm of the abdominal aorta greater than 5.0 cm.*

         17. Previous kidney transplant

         18. a. Stenosis of greater than 50% of a previously treated revascularized renal artery OR
             b. Treatment of any renal artery stenosis within the past 9 months (roll-in patients
             can have prior treatment on the contralateral side)

         19. Kidney size less than 7 cm. supplied by target vessel

         20. Hydronephrosis, nephritis or other known cause of renal insufficiency, not due to
             large vessel renal artery stenosis

         21. Visualized stenosis of only an accessory renal artery supplying greater than 1/2 of
             the ipsilateral renal parenchyma, without stenosis in a dominant renal artery

         22. Local lab serum Cr greater than 4.0 mg/dl on the day of randomization*

         23. Presence of a renal artery stenosis not amenable for treatment with a stent, known to
             be present prior to randomization

               1. The index lesion cannot be treated with a single stent (i.e. greater than 18 mm.
                  in length)

               2. The placement of a stent will necessitate covering a renal artery branch renal
                  artery with a stent

               3. The stenosis is in an artery less than 3.5 mm. in diameter

               4. The stenosis involves a segmental renal artery branch

         24. Abrupt vessel closure or dissection after diagnostic angiography [NOTE: Patients with
             abrupt vessel closure or dissection as a result of diagnostic angiography will not be
             randomized but will undergo stent revascularization, receive optimal medical therapy
             and will be followed for the full study period] *Roll-in patients do not need to meet
             these inclusion/exclusion criteria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Cohen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mid-America Heart Institute, St. Luke's Hospital, Kansas City, MO</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christopher J. Cooper, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Toledo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Donald Cutlip, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medcial Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alan Matsumoto, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Virginia School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Steffes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota - Clinical and Translational Science Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Timothy P Murphy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rhode Island Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Scott D Solomon, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lance D Dworkin, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Rhode Island Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Toledo</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Cooper CJ, Murphy TP, Matsumoto A, Steffes M, Cohen DJ, Jaff M, Kuntz R, Jamerson K, Reid D, Rosenfield K, Rundback J, D'Agostino R, Henrich W, Dworkin L. Stent revascularization for the prevention of cardiovascular and renal events among patients with renal artery stenosis and systolic hypertension: rationale and design of the CORAL trial. Am Heart J. 2006 Jul;152(1):59-66.</citation>
    <PMID>16824832</PMID>
  </reference>
  <reference>
    <citation>Murphy TP, Cooper CJ, Dworkin LD, Henrich WL, Rundback JH, Matsumoto AH, Jamerson KA, D'Agostino RB. The Cardiovascular Outcomes with Renal Atherosclerotic Lesions (CORAL) study: rationale and methods. J Vasc Interv Radiol. 2005 Oct;16(10):1295-300.</citation>
    <PMID>16221898</PMID>
  </reference>
  <results_reference>
    <citation>Bittl JA. Treatment of atherosclerotic renovascular disease. N Engl J Med. 2014 Jan 2;370(1):78-9. doi: 10.1056/NEJMe1313423. Epub 2013 Nov 18.</citation>
    <PMID>24245567</PMID>
  </results_reference>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 19, 2004</study_first_submitted>
  <study_first_submitted_qc>April 20, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 21, 2004</study_first_posted>
  <results_first_submitted>December 9, 2013</results_first_submitted>
  <results_first_submitted_qc>December 9, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 29, 2014</results_first_posted>
  <last_update_submitted>September 18, 2015</last_update_submitted>
  <last_update_submitted_qc>September 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 5, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Renal Artery Obstruction</mesh_term>
    <mesh_term>Hypertension, Renovascular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candesartan cilexetil</mesh_term>
    <mesh_term>Candesartan</mesh_term>
    <mesh_term>Amlodipine, atorvastatin drug combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Optimal Medical Therapy</title>
          <description>Optimal anti-hypertensive therapy
Atacand/HCT, Caduet: Atacand/HCT and caduet or optimal medical therapy for hypertension</description>
        </group>
        <group group_id="P2">
          <title>Stenting</title>
          <description>Stent procedure plus optimal anti-hypertensive therapy
GENESISTM Embolic Protection Stent and Angioguard Device (Angioplasty plus stenting): Angioplasty plus stenting of the renal artery GENESISTM Embolic Protection Stent and Angioguard Device</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="480"/>
                <participants group_id="P2" count="467"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="472"/>
                <participants group_id="P2" count="459"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>scientific integrity issue</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Optimal Medical Therapy</title>
          <description>Optimal anti-hypertensive therapy
Atacand/HCT, Caduet: Atacand/HCT and caduet or optimal medical therapy for hypertension</description>
        </group>
        <group group_id="B2">
          <title>Stenting</title>
          <description>Stent procedure plus optimal anti-hypertensive therapy
GENESISTM Embolic Protection Stent and Angioguard Device (Angioplasty plus stenting): Angioplasty plus stenting of the renal artery GENESISTM Embolic Protection Stent and Angioguard Device</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="472"/>
            <count group_id="B2" value="459"/>
            <count group_id="B3" value="931"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69" spread="9.0"/>
                    <measurement group_id="B2" value="69.3" spread="9.4"/>
                    <measurement group_id="B3" value="69.15" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="140"/>
                    <measurement group_id="B2" value="127"/>
                    <measurement group_id="B3" value="267"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="332"/>
                    <measurement group_id="B2" value="332"/>
                    <measurement group_id="B3" value="664"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="241"/>
                    <measurement group_id="B2" value="225"/>
                    <measurement group_id="B3" value="466"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="231"/>
                    <measurement group_id="B2" value="234"/>
                    <measurement group_id="B3" value="465"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="387"/>
                    <measurement group_id="B2" value="385"/>
                    <measurement group_id="B3" value="772"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Composite Endpoint: Death From Cardiovascular or Renal Causes, Stroke, Myocardial Infarction, Hospitalization for CHF, Progressive Renal Insufficiency, or Permanent Renal Replacement Therapy</title>
        <description>Only the first event per participant is included in the composite</description>
        <time_frame>Measured at every 3 months for the first year and annually thereafter</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Optimal Medical Therapy</title>
            <description>Optimal anti-hypertensive therapy
Atacand/HCT, Caduet: Atacand/HCT and caduet or optimal medical therapy for hypertension</description>
          </group>
          <group group_id="O2">
            <title>Stenting</title>
            <description>Stent procedure plus optimal anti-hypertensive therapy
GENESISTM Embolic Protection Stent and Angioguard Device (Angioplasty plus stenting): Angioplasty plus stenting of the renal artery GENESISTM Embolic Protection Stent and Angioguard Device</description>
          </group>
        </group_list>
        <measure>
          <title>Composite Endpoint: Death From Cardiovascular or Renal Causes, Stroke, Myocardial Infarction, Hospitalization for CHF, Progressive Renal Insufficiency, or Permanent Renal Replacement Therapy</title>
          <description>Only the first event per participant is included in the composite</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="472"/>
                <count group_id="O2" value="459"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="169" lower_limit="0.76" upper_limit="1.17"/>
                    <measurement group_id="O2" value="161" lower_limit="0.76" upper_limit="1.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cardiovascular or Renal Death</title>
        <time_frame>Measured at every 3 months for the first year and annually thereafter</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Optimal Medical Therapy</title>
            <description>Optimal anti-hypertensive therapy
Atacand/HCT, Caduet: Atacand/HCT and caduet or optimal medical therapy for hypertension</description>
          </group>
          <group group_id="O2">
            <title>Stenting</title>
            <description>Stent procedure plus optimal anti-hypertensive therapy
GENESISTM Embolic Protection Stent and Angioguard Device (Angioplasty plus stenting): Angioplasty plus stenting of the renal artery GENESISTM Embolic Protection Stent and Angioguard Device</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiovascular or Renal Death</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="472"/>
                <count group_id="O2" value="459"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Myocardial Infarction</title>
        <time_frame>Measured at every 3 months for the first year and annually thereafter</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Optimal Medical Therapy</title>
            <description>Optimal anti-hypertensive therapy
Atacand/HCT, Caduet: Atacand/HCT and caduet or optimal medical therapy for hypertension</description>
          </group>
          <group group_id="O2">
            <title>Stenting</title>
            <description>Stent procedure plus optimal anti-hypertensive therapy
GENESISTM Embolic Protection Stent and Angioguard Device (Angioplasty plus stenting): Angioplasty plus stenting of the renal artery GENESISTM Embolic Protection Stent and Angioguard Device</description>
          </group>
        </group_list>
        <measure>
          <title>Myocardial Infarction</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="472"/>
                <count group_id="O2" value="459"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Hospitalization for Congestive Heart Failure</title>
        <time_frame>Measured at every 3 months for the first year and annually thereafter</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Optimal Medical Therapy</title>
            <description>Optimal anti-hypertensive therapy
Atacand/HCT, Caduet: Atacand/HCT and caduet or optimal medical therapy for hypertension</description>
          </group>
          <group group_id="O2">
            <title>Stenting</title>
            <description>Stent procedure plus optimal anti-hypertensive therapy
GENESISTM Embolic Protection Stent and Angioguard Device (Angioplasty plus stenting): Angioplasty plus stenting of the renal artery GENESISTM Embolic Protection Stent and Angioguard Device</description>
          </group>
        </group_list>
        <measure>
          <title>Hospitalization for Congestive Heart Failure</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="472"/>
                <count group_id="O2" value="459"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Stroke</title>
        <time_frame>Measured at every 3 months for the first year and annually thereafter</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Optimal Medical Therapy</title>
            <description>Optimal anti-hypertensive therapy
Atacand/HCT, Caduet: Atacand/HCT and caduet or optimal medical therapy for hypertension</description>
          </group>
          <group group_id="O2">
            <title>Stenting</title>
            <description>Stent procedure plus optimal anti-hypertensive therapy
GENESISTM Embolic Protection Stent and Angioguard Device (Angioplasty plus stenting): Angioplasty plus stenting of the renal artery GENESISTM Embolic Protection Stent and Angioguard Device</description>
          </group>
        </group_list>
        <measure>
          <title>Stroke</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="472"/>
                <count group_id="O2" value="459"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>30% Reduction of eGFR From Baseline, Persisting for Greater Than or Equal to 60 Days</title>
        <time_frame>Measured at every 3 months for the first year and annually thereafter</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Optimal Medical Therapy</title>
            <description>Optimal anti-hypertensive therapy
Atacand/HCT, Caduet: Atacand/HCT and caduet or optimal medical therapy for hypertension</description>
          </group>
          <group group_id="O2">
            <title>Stenting</title>
            <description>Stent procedure plus optimal anti-hypertensive therapy
GENESISTM Embolic Protection Stent and Angioguard Device (Angioplasty plus stenting): Angioplasty plus stenting of the renal artery GENESISTM Embolic Protection Stent and Angioguard Device</description>
          </group>
        </group_list>
        <measure>
          <title>30% Reduction of eGFR From Baseline, Persisting for Greater Than or Equal to 60 Days</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="472"/>
                <count group_id="O2" value="459"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Need for Renal Replacement Therapy</title>
        <time_frame>Measured at every 3 months for the first year and annually thereafter</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Optimal Medical Therapy</title>
            <description>Optimal anti-hypertensive therapy
Atacand/HCT, Caduet: Atacand/HCT and caduet or optimal medical therapy for hypertension</description>
          </group>
          <group group_id="O2">
            <title>Stenting</title>
            <description>Stent procedure plus optimal anti-hypertensive therapy
GENESISTM Embolic Protection Stent and Angioguard Device (Angioplasty plus stenting): Angioplasty plus stenting of the renal artery GENESISTM Embolic Protection Stent and Angioguard Device</description>
          </group>
        </group_list>
        <measure>
          <title>Need for Renal Replacement Therapy</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="472"/>
                <count group_id="O2" value="459"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Optimal Medical Therapy</title>
          <description>Optimal anti-hypertensive therapy
Atacand/HCT, Caduet: Atacand/HCT and caduet or optimal medical therapy for hypertension</description>
        </group>
        <group group_id="E2">
          <title>Stenting</title>
          <description>Stent procedure plus optimal anti-hypertensive therapy
GENESISTM Embolic Protection Stent and Angioguard Device (Angioplasty plus stenting): Angioplasty plus stenting of the renal artery GENESISTM Embolic Protection Stent and Angioguard Device</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="283" subjects_at_risk="472"/>
                <counts group_id="E2" subjects_affected="290" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood and Lymphatic System Disorders</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="472"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Disorders</sub_title>
                <counts group_id="E1" events="117" subjects_affected="117" subjects_at_risk="472"/>
                <counts group_id="E2" events="128" subjects_affected="128" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Congenital, Familial and Genetic Disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="472"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear and Labyrinth Disorders</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="472"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye Disorders</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="472"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal Disorders</sub_title>
                <counts group_id="E1" events="42" subjects_affected="42" subjects_at_risk="472"/>
                <counts group_id="E2" events="57" subjects_affected="57" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General Disorders</sub_title>
                <counts group_id="E1" events="38" subjects_affected="38" subjects_at_risk="472"/>
                <counts group_id="E2" events="36" subjects_affected="36" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatobiliary Disorders</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="472"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Immune System Disorders</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="472"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and Infestations</sub_title>
                <counts group_id="E1" events="69" subjects_affected="69" subjects_at_risk="472"/>
                <counts group_id="E2" events="63" subjects_affected="63" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury, Poisoning and Procedural Complications</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="472"/>
                <counts group_id="E2" events="42" subjects_affected="42" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Investigations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="472"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolism and Nutrition Disorders</sub_title>
                <counts group_id="E1" events="28" subjects_affected="28" subjects_at_risk="472"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musuloskeletal and Connective Tissue Disorders</sub_title>
                <counts group_id="E1" events="31" subjects_affected="31" subjects_at_risk="472"/>
                <counts group_id="E2" events="39" subjects_affected="39" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasms Benign, Malignant and Unspecified</sub_title>
                <counts group_id="E1" events="26" subjects_affected="26" subjects_at_risk="472"/>
                <counts group_id="E2" events="27" subjects_affected="27" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervous System Disorders</sub_title>
                <counts group_id="E1" events="67" subjects_affected="67" subjects_at_risk="472"/>
                <counts group_id="E2" events="61" subjects_affected="61" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="441" subjects_at_risk="472"/>
                <counts group_id="E2" subjects_affected="429" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood and Lymphatic System Disorders</sub_title>
                <counts group_id="E1" events="93" subjects_affected="93" subjects_at_risk="472"/>
                <counts group_id="E2" events="85" subjects_affected="85" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Disorders</sub_title>
                <counts group_id="E1" events="205" subjects_affected="205" subjects_at_risk="472"/>
                <counts group_id="E2" events="201" subjects_affected="201" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear and Labyrinth Disorders</sub_title>
                <counts group_id="E1" events="24" subjects_affected="24" subjects_at_risk="472"/>
                <counts group_id="E2" events="32" subjects_affected="32" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye Disorders</sub_title>
                <counts group_id="E1" events="63" subjects_affected="63" subjects_at_risk="472"/>
                <counts group_id="E2" events="60" subjects_affected="60" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General Disorders</sub_title>
                <counts group_id="E1" events="261" subjects_affected="261" subjects_at_risk="472"/>
                <counts group_id="E2" events="251" subjects_affected="251" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury, Poisoning and Procedural Complications</sub_title>
                <counts group_id="E1" events="122" subjects_affected="122" subjects_at_risk="472"/>
                <counts group_id="E2" events="133" subjects_affected="133" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Investigations</sub_title>
                <counts group_id="E1" events="125" subjects_affected="125" subjects_at_risk="472"/>
                <counts group_id="E2" events="124" subjects_affected="124" subjects_at_risk="459"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Patients could be enrolled in the trial with renal artery stenosis &gt; = 60%. Didn't include patients with fibromuscular dysplasia. Some screened and deemed to be eligible were not enrolled because of physician preference.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Christopher Cooper, MD</name_or_title>
      <organization>University of Toledo</organization>
      <phone>419-383-6297</phone>
      <email>christopher.cooper@utoledo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

